Thermo Fisher Scientific Inc.
TMO Healthcare Diagnostics & Research
Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS grew 9.35%, free cash flow grew 51.8% and total debt rose 18.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow TMO
Thermo Fisher Scientific Inc. (TMO) Revenue
Thermo Fisher Scientific Inc.'s revenue for fiscal 2025 was $44.6B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $46.3B. Over the past ten years it has ranged from $17.0B (fiscal 2015) to $44.9B (fiscal 2022); the current reading is higher than 91% of that period. Thermo Fisher Scientific Inc. ranks 1st of 50 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $44.6B | 3.91% |
| FY2024 | $42.9B | 0.05% |
| FY2023 | $42.9B | (4.58%) |
| FY2022 | $44.9B | 14.55% |
| FY2021 | $39.2B | 21.71% |
| FY2020 | $32.2B | 26.14% |
| FY2019 | $25.5B | 4.86% |
| FY2018 | $24.4B | 16.45% |
| FY2017 | $20.9B | 14.47% |
| FY2016 | $18.3B | 7.72% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $12.0B | 8.99% |
| Mar 2026 | $11.0B | (9.91%) |
| Dec 2025 | $12.2B | 9.83% |
| Sep 2025 | $11.1B | 2.46% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| TMO Thermo Fisher Scientific Inc. | $46.3B |
| DHR Danaher Corporation compare | $25.1B |
| IQV IQVIA Holdings Inc. compare | $17.0B |
| A Agilent Technologies, Inc. compare | $7.4B |
| WAT Waters Corporation compare | $4.6B |
| IDXX IDEXX Laboratories, Inc. compare | $4.6B |
| ILMN Illumina, Inc. compare | $4.5B |
| MTD Mettler-Toledo International, Inc. compare | $4.1B |
| NTRA Natera, Inc. compare | $2.7B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on TMO
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement